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Abstract
Aims Conflicting data have been reported with regard to
Hashimoto thyroiditis (HT) and risk of malignancy. The
aim of this study was to evaluate coexistence of papillary
thyroid cancer (PTC) with HT.
Patients and methods This is a retrospective cohort study in
which HTwas diagnosed in 452 (F/M ratio0405:47, median
age 53.5±12.1 years) of 7,545 patients qualified for thy-
roidectomy throughout the years 2002 to 2010. Pathological
reports were reviewed to identify prevalence of PTC in HT
vs. non-HT patients.
Results PTC was diagnosed in 106 of 452 (23.5 %) HT
patients vs. 530 of 7,093 (7.5 %) non-HT patients (p<
0.001). Metastases to level VI lymph nodes were observed
in 81 of 106 (76.4 %) patients with PTC in HT vs. 121 of 530
(22.8 %) patients with PTC in non-HT disease (p<0.001).
Conclusions HT was associated with a threefold increase of
PTC prevalence as compared to other non-HT thyroid dis-
eases, and the spread of PTC to level VI lymph nodes was
four times more frequent in HT than in non-HT patients.
Keywords Hashimoto thyroiditis . Papillary thyroid
carcinoma . Benign thyroid disease
Introduction
Autoimmune thyroid disease known as Hashimoto thyroid-
itis (HT) is one of special forms of chronic thyroiditis and
the most common non-iatrogenic cause of hypothyroidism.
The condition is definitely more prevalent in female popu-
lation (M/F ratio of 1:10, 1:20), is seen in each age group,
and may also affect children and adolescents. Its unclear
etiopathogenesis strongly indicates an autoimmune back-
ground, associated with T-helper lymphocyte (CD4+) acti-
vation by class II human leukocyte antigen system cells
(MHC class II: HLA-DR3, HLA-DR4, HLA-DR5). On the
one hand, the cells recruit cytotoxic lymphocytes (Tc, CD8
+), thus facilitating a release of cytokines that damage
thyroid follicular cells and, on the other hand, activating B
lymphocytes; they facilitate production of specific anti-
microsomal, anti-thyroglobulin, or anti-TSH receptor anti-
bodies. Described for the first time in 1912, the disease may
have two distinct histological forms: atrophic and nodular.
Clinically, in the majority of cases, it is characterized by
hypothyroidism, although in a small number of patients, it
may be preceded by symptoms of hyperthyroidism. The as-
sociation between coexistence of Hashimoto thyroiditis and
papillary thyroid cancer (PTC) was first described byDailey et
al. in 1955. Since that time, attempts have been made at
elucidation of this phenomenon. The objective of the present
paper was to demonstrate coexistence of HT with an autoim-
mune background with highly differentiated thyroid cancer
and to attempt to determine assumptions for further therapeu-
tic management and prognosis in patients operated on for
Hashimoto thyroiditis and papillary thyroid cancer.
An early detection of lesions, a careful selection of a
surgical strategy in a referral center, target-based adjuvant
therapy, and treatment monitoring may have a significant
impact on improvement of therapeutic outcomes and quality
of life in patients with the disease [1, 2].
The study was presented at the 5th Biennial Congress of ESES in
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Materials and methods
A retrospective analysis included 452 patients diagnosed
with Hashimoto thyroiditis and coexisting papillary thyroid
cancer selected from among 7,545 patients treated surgically
in a single clinical referral center in the years 2002–2010.
The mean age of the investigated group was 53.5±12.1 years
and the F/M ratio was 405:47. The demographics of the
investigated group are presented in Table 1. Assessment of
the clinical stage was based on the seventh edition of the
TNM system (2010), while histopathology results were
classified based on a reanalysis of pathology reports pertain-
ing to materials stored in the Histology Department
Records. The diagnosis of Hashimoto thyroiditis was de-
fined as the presence of lymphocytic infiltrations in the
thyroid parenchyma and stroma, with formation of reaction
centers and lymphoid nodules and presence of oxyphilic
cells. The lymph nodes were characterized by nonspecific
reactive lesions. High levels of anti-peroxidase antibodies
confirmed the diagnosis. The extent of primary surgery
performed in the presented group included total thyroidec-
tomy with central compartment lymph node dissection in
91 % patients; in the remaining cases, bilateral subtotal
thyroid lobectomies were done. Histopathology confirming
cancer presence constituted an indication for total resection
of the residual thyroid tissue.
All the patients qualified for surgical treatment were sub-
jected to thyroid ultrasonography, determinations of free thy-
roid hormones (fT4, fT3), thyrotropic hormone (TSH), as well
as anti-thyroid peroxidase (TPO) and anti-thyroglobulin (TG)
antibodies. The inclusion criteria for surgery in the HT group
included nodular lesions of the thyroid detected by ultrasound
as hypoechoic or hyperechoic nodular pattern at least 5 mm in
diameter, identification of a perinodular hypoechogenic or
hyperechogenic halo, and the presence of an anechoic lesion
with a reinforced posterior wall. A repeated analysis of fine-
needle aspiration biopsy (FNAB) results based on the
Bethesda 2009 classification showed that in the test results,
the predominating lesions were these that today would be
classified as groups III and IV of the above classification
system. In the non-HT group, surgical treatment was indicated
in case of suspicious lesions detected by FNAB (groups III–
VI according to Bethesda 2009), symptoms of tracheal and
surrounding tissue compression, multinodular toxic goiter,
and Graves’ disease. Prior to surgical treatment, all the
patients presenting with clinical and biochemical hypothyreo-
sis received levothyroxine substitution. The mean follow-up
time in the analyzed group was 4.3±2.1 years. In the first
postoperative day, indirect laryngoscopy was performed in all
the patients and their calcium levels were determined; hypo-
calcemia was assumed at total calcium levels below 2.0 mmol/
l. Following thyroidectomy and the diagnosis of differentiated
thyroid carcinoma, a uniform model of therapeutic manage-
ment was employed in all the patients; the model consisted of
radioiodine adjuvant treatment in case of tumors with a diam-
eter of >10 mm, administration of L-thyroxine (at a dose
ensuring the suppression level for TSH range of 0.1–
0.3 mU/l), and strict periodic follow-up determination of
hormones and anti-TG.
Statistical analysis for normally distributed variables
employed the Student’s t test in comparisons, while the
remaining variables were analyzed using the χ2 test. When
the test assumptions were not fulfilled, comparisons were
based on the so-called Fisher’s exact test. The criterion of
including a variable into the model was p<0.05.
Results
In the analyzed group of 452 patients with Hashimoto
thyroiditis, 106 (23.5 %) cases of papillary thyroid cancer
(HT-PTC) were detected as compared to 530 (7.5 %) cancer
patients in the group of 7,093 individuals (non-HT-PTC)
without diagnosed autoimmune disease. The values are sta-
tistically significant (p<0.001). Both the analyzed groups
showed a similar ratio of males to females (1:9 in HT-PTC
group vs. 1:10 in non-HT-PTC group) and a similar mean
age of the patients (53.5±12.1 years in HT-PTC group vs.
52.3±15.5 years in non-HT-PTC group). A statistically sig-
nificant difference was observed in preoperative goiter vol-
ume as determined by ultrasonography (22.1±18.2 ml in
HT-PTC group vs. 96.2±40.4 ml in non-HT-PTC group, p<
0.001). FNAB was performed in all the patients with nodu-
lar lesions above 5 mm in diameter, but in the HT-PTC
group, only 31 (29.2 %) of 106 HT-PTC subjects had
thyroid tumor diagnosed preoperatively. In the remaining
cases, cytological material did not raise any suspicions of
neoplastic process. In FNAB smears, oxyphilic cells with
Table 1 Demographic characteristics of 7,545 patients analyzed in
this study
HT (n0452) Non-HT
(n07,093)
p value
Gender ratio (M/F) 47:405 667:6,426 0.484
Average age (years) 53.5±12.1 52.3±15.5 0.739
Preoperative thyroid volume
in ml (by ultrasound),
mean ± SD
22.1±18.2 96.2±40.4 <0.001a
Preoperative diagnosis, n (%)
Benign thyroid disease (BTD) 421 (93.1) 6,881 (97.0) <0.001
Positive FNAB for PTC 31 (29.2) 212 (40.0) <0.001
BTD multinodular nontoxic goiter, multinodular toxic goiter, Graves
disease, and Hashimoto disease, FNAB fine-needle aspiration biopsy,
PTC papillary thyroid cancer
a t test was used for statistical analysis
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lymphocytes and macrophages predominated (Table 1). In
eight (12.3 %) patients (pT1a 0 65) with a nodule of 8–
10 mm in size, FNAB confirmed thyroid microcarcinoma.
In one case, in a 4-mm nodule, a focus of papillary thyroid
carcinoma was detected preoperatively. The above lesions
were seen in females in a lower age range as compared to
the entire group (16–46 years).
However, prevalence of suspicious FNAB cytology in
non-HT-PTC group was significantly higher and equal to
212 (40.0 %) of 530 patients (p<0.001). pT1a stage papillary
thyroid carcinoma predominated in patients with Hashimoto
thyroiditis as compared to the remaining analyzed patients.
The values were 65 (14.4 %) in HT-PTC vs. 301 (4.24 %) in
non-HT-PTC (p<0.001). A similar distribution was ob-
served in the group with the multifocal form of papillary
thyroid cancer (pT1m): 22 (4.9 %) in HT-PTC vs. 119
(1.7 %) in non-HT-PTC, although the differences were not
significant. Multifocality was defined as the presence of ≥2
cancer foci in one or both thyroid lobes. A statistically
significant difference was noted with respect to nodal me-
tastases in the central cervical compartment (compartment
VI). Such metastases were observed in 81 of 106 (76.4 %)
patients with HT-PTC and only in 121 of 530 (22.8 %) non-
HT-PTC patients (p<0.001). The metastases were particu-
larly common in pT1a papillary thyroid cancer: 46 (43.4 %)
in HT-PTC vs. 29 (5.47 %) in non-HT-PTC. The mean size
of the largest single focus in the HT-PTC group was 7.61±
5.78; nevertheless, in a high number of patients (pT1m: HT-
PTC022 (4.9 %)), the lesions were 2–3 mm in size and were
noted in both thyroid lobes (Table 2). In HT patients, prep-
arations of cervical compartment lymph nodes showed a
higher number of dissected lymph nodes and a higher num-
ber of metastatically involved lymph nodes as compared to
non-HT patients (Table 2).
No significant differences were observed between HT-PTC
patients and non-HT-PTC patients (Table 3) with regard to the
prevalence of complications following thyroidectomy.
Discussion
An unambiguous association between papillary thyroid cancer
and Hashimoto thyroiditis was demonstrated for the first time
by Dailey et al. in 1955 [1]. According to abundant data from
the literature on the subject [2–9, 17, 21–24, 34, 37, 38] and a
meta-analysis performed by Singh et al. [2], PTC coexisted
with Hashimoto thyroiditis 2.8 more frequently and its prev-
alence investigated in patient groups as reported in various
articles ranged from 0.5 to 30 % (Table 4). PTC was also
observed to occur almost twice as often as other types of
thyroid cancer. In the presently analyzed material, in as many
as 23.5 % patients, papillary thyroid cancer arose from lesions
characterized as chronic autoimmune thyroiditis. This
percentage constituted a threefold increase of the number of
PTC cases in the population of Hashimoto thyroiditis patients
as compared to the overall number of individuals with papil-
lary thyroid cancer in the investigated group (non-HT-PTC0
530 patients). The above quoted data from literature and the
results of our observations clearly point to an increase in
neoplastic disease prevalence in patients suffering from an
autoimmune disease. To date, there are no unambiguous indi-
cations for determining whether an autoimmune disease
Table 2 Final histopathology diagnosis after thyroidectomy in 7,545
patients involved in this study
HT (n0452) Non-HT
(n07,093)
p value
Papillary thyroid cancer, no. (%)
Total 106 (23.5) 530 (7.5) <0.001
TNM classification
Primary tumor
pT1aNxMx 65 (61.3) 301 (56.7) <0.001
pT1bNxMx 18 (17.0) 45 (8.4) <0.001
pT1mNxMx 22 (20.8) 119 (22.4) 0.01
pT2NxMx 1 (0.9) 66 (12.5) <0.001
Regional lymph nodes
pT1aN1aMx 46 (43.4) 29 (5.5) <0.001
pT1bN1aMx 16 (15.1) 41 (7.7) <0.001
pT1mN1aMx 18 (17.0) 43 (8.1) <0.001
pT2N1aMx 1 (0.9) 8 (1.5) 0.07
Diameter of the largest foci in mm
(mean ± SD)
7.6±5.8 9.4±6.9 0.01
Number of removed lymph nodes
within level VI (mean ± SD)
12.7±3.7 6.5±2.4 <0.001
Number of macrometastatic lymph
nodes (mean ± SD)
6.4±2.7 2.1±1.0 <0.001
Table 3 Complications after thyroidectomy in 636 patients involved
in this study
PTC in HT
(n0106)
PTC in non-
HT (n0530)
p value
Parathyroid found in pathological
report, no. (%)
5 (4.7) 27 (5.1) 0.871
Hypoparathyroidism after operation, no. (%)
Total 47 (44.3) 209 (39.4) 0.347
Transient 45 (42.4) 197 (37.2) 0.306
Permanent 2 (1.9) 12 (2.3) 0.809
Unilateral RLN injury, no. (%)
Total 12 (5.7) 55 (5.2) 0.766
Transient 9 (4.2) 41 (3.9) 0.792
Permanent 3 (1.4) 14 (1.3) 0.909
Calculation was made for nerves at risk, not for patients (there were
212 nerves at risk in PTC in HT group and 1,060 nerves at risk in PTC
in non-HT group). Chi-squared test was employed for all values
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predisposes the patient to develop cancer or whether in the
course of carcinogenesis-associated cellular transformations,
there occurs a change in autoimmune responses that would
facilitate the development of such a disease. Segal et al. [10]
suggest that Hashimoto thyroiditis does not determine but
rather delays cancer development, while circulating antibodies
may constitute a significant factor preventing tumor develop-
ment and nodal metastases. This thesis is in opposition to the
investigations by Di Pasquale et al. [11] that suggest the very
autoimmune background in all cases of cancer coexisting with
Hashimoto thyroiditis. The hypothesis assumes an increased
genetic predisposition to the development of neoplastic lesions.
Information on molecular factors that determine initiation,
promotion, and progression of thyroid cancers has been the
subject matter of numerous investigations in recent years. In
keeping with the theory of multistage carcinogenesis, various
phenotypic variants of thyroid tumors may develop through
genetic defects of the signaling cascade, via activation and
inactivation of oncogenes and serial mutations. Presently, the
best known form of such alterations in papillary thyroid cancer
is the concept of oncogenic RET/PTC1 and RET/PTC3
sequences that are also present in chronic lymphocytic thyroid-
itis, but with no clinical manifestation of lesions in the thyroid
parenchyma [12, 13]. The RET/PTC1 mutation was detected
by Sheils et al. in as many as 95 % of investigated patients with
Hashimoto thyroiditis [14]. In the aforementioned reports, the
authors suggest that the presence of mutations involving the
RET/PTC oncogenes may be an early molecular indicator of
papillary thyroid microcarcinoma lesions. Recent experience
with the use of PCR in cytological diagnostic management of
material obtained by FNAB may be of importance in detecting
neoplastic lesions before they become clinically manifested
[15]. The significance of molecular studies as an element of
cytological diagnostics of thyroid lesions is confirmed by con-
siderable differences in papillary thyroid cancer diagnoses in
biopsy materials. According to literature [2, 16–21], histology-
confirmed diagnoses of papillary thyroid cancer fall within an
extremely wide range from 0.4% in the reports byMatesa et al.
[17] to 92 % in keeping with the data provided by Singh et al.
[2, 21]. In our material, in 31 of 452 (6.9 %) HT patients,
confirmation of the diagnosis of papillary thyroid carcinoma in
material collected by targeted fine-needle aspiration biopsy was
achieved, which accounted only for 29.2 % of all HT-PTC
diagnoses established based on final histopathology. The rea-
son behind such significant differences lies in difficulties in
defining lesions that require cytological diagnostics. In all
nodular, localized lesions situated within the thyroid parenchy-
ma, specificity and sensitivity were high, ranking between 87
and 92 %. In atrophic Hashimoto thyroiditis with increased
tissue density, false-negative results predominated. This hap-
pened due to lymphocytic infiltrations with reaction center
formation both in the thyroid tissue and around the suspected
primary focus. Some authors believe the presence of such
infiltrations to be a factor predisposing to tumor development
[2, 22], while others regard it as a response of the body to
neoplastic disease, hence the potentially better prognosis in this
group of patients [2, 9, 23–25]. Kebebew et al. [23] firmly
indicate that the presence of chronic lymphocytic thyroiditis in
patients with papillary thyroid cancer improves the prognosis.
On the other hand, it cannot be at the same time an independent
prognostic factor indicating a lower number of recurrences or
the presence of nodal metastases. This common transformation
path of thyroid cells in papillary thyroid cancer and Hashimoto
thyroiditis has been also attempted to be explained by similar-
ities in activation of the metabolic cycle of tyrosine kinases
(PI3k/Akt pathway) and overexpression of p63 protein that
leads to apoptosis inhibition [26, 27].
Another extremely important element that plays a role in
clinical assessment of papillary thyroid cancer is the size of the
primary focus. Tumors up to 10 mm in diameter are charac-
terized by a favorable prognosis, although they may demon-
strate all specific properties of a malignancy, with possible
nodal metastasizing, capsular infiltration, or multifocal growth
in the thyroid tissue. Bradley et al. [28] analyzed a group of
accidentally detected forms of papillary thyroid cancer (687
patients, 81 IPTC (12%)) and confirmed this tumor form in as
many as 21 (28 %) patients of 74 individuals with Hashimoto
thyroiditis. The primary focus size did not exceed 7 mm.
(mean 2.8±1.7 mm). In the present analysis, although the
mean focus size was larger as compared to the above-
mentioned values, it did not exceed 10 mm in diameter, thus
Table 4 Coexistence Hashimoto thyroiditis with papillary thyroid
cancer
Authors Patient included
in the study
HT with PTC,
n (%)
Dailey at al. [1] 278 with PTC 35 (12.6)
Singh et al. [2] 388 with PTC 57 (15.0)
Chesky VE et al. [3] 432 with HT 48 (11.1)
Ott et al. [6] 161 with TC 61 (38.0)
Eisenberg et al. [7] 120 with TC 13 (10.8)
Sclafani et al. [8] 48 with HT 18 (17.0)
Schäffler et al. [9] 153 with TC 10 (6.5)
Matesa-Anić et al. [17] 10,508 FNAB 42 (0.5)
Cipolla et al. [20] 71 with PTC 19 (26.7)
Pisanu et al. [21] 344 with PTC 33 (9.6)
Kebebew et al. [23] 136 with PTC 41 (30)
Matsubayashi et al. [24] 95 with PTC 36 (37.9)
Yoon et al. [34] 195 with PTC 56 (28.7)
Paulson et al. [37] 139 with PTC 61 (43.8)
Repplinger et al. [38] 217 with HT 63 (29)
Literature review was used in this study
HT Hashimoto thyroiditis, TC thyroid cancer, PTC papillary thyroid
cancer, FNAB fine-needle aspiration biopsy
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providing the basis for microcarcinoma diagnosis. In the
analyzed material, microcarcinomas were markedly predom-
inant (65 cases061.3 %). Of significance is also a relatively
high number (22020.8 %) of patients with multifocal PTC
form and with foci with the diameter starting from 2 to 5 mm.
Based on the analysis, one may thus surmise that coexistence
of an autoimmune disease and papillary thyroid cancer did not
limit the number of primary foci and affected their size only
[29, 30]. The above data have been quite extensively con-
firmed in the literature on the subject. Numerous authors are
inclined to believe that coexistence of lymphocytic infiltra-
tions, positive history of thyroid autoimmune diseases, or
significantly high antibody levels (anti-TPO, anti-TG) prior
to surgery had a significant impact on prognosis improvement.
Although there have been voiced opinions that such factors
did not affect mortality rates, they undoubtedly determined
early initiation of targeted therapy [30].
Tumor grading determined by the degree of capsular infil-
tration and nodal metastasizing allows for selecting patients
with a poor prognosis. As it has been mentioned previously,
papillary thyroid cancer is generally characterized by a good
prognosis. This is particularly true in patients with highly
differentiated pT1a cancers that do not exceed 10 mm in
diameter. It should be noted, however, that even these forms
show a fairly high ability to metastasize. In their analysis of
203 patients with papillary thyroid microcarcinoma, So et al.
found nodal metastases in as many as 24.6 % of subjects,
multifocal cancer in 31 %, and capsular infiltrations in 20.7 %
of their surgical patients [31]. Similar observations were made
by Mercante et al. and Cho et al. [32, 33], who emphasized
that the size of the primary focus did not play a role in the
presence or absence of nodal metastases or capsular infiltra-
tions. Is there, then, any difference in tumor morphology,
ability to metastasize, and prognosis in patients with papillary
thyroid cancer and Hashimoto thyroiditis?
In the entire presently analyzed material, the presence of
central compartment lymph node metastases was significantly
higher in patients with cancer and Hashimoto thyroiditis (PTC-
HT081 (76.4 %) vs. non-HT-PTC0121 (22.8 %)). According
to numerous reports, metastatic foci in cervical lymph nodes
accompany both “clear” cancer forms and tumors presenting
with symptoms of chronic lymphocytic thyroiditis. The
degree of nodal involvement—differently reported in various
publications—ranged from 7 to 49 % [34–36]. In one of the
recent articles, Paulson et al. [37] suggest that a lower number
of nodal metastases to the central compartment are a result of a
coexisting autoimmune disease and the protective role it plays
in neoplastic spreads beyond the primary focus area.
Based on our observations of both groups of patients, a
conclusion has been formulated that concomitant Hashimoto’s
thyroiditis and papillary thyroid carcinoma are more common
phenomena than previously believed, since they are observed
in approximately 20 % of all cases of this cancer type.
According to data from the literature on the subject, it is
significantly more common among women from younger age
groups, is characterized by lesions with a small diameter of the
primary focus, and, at times, has a multifocal form, but the
prognosis is statistically more favorable as compared to other
patient groups [20, 38]. Improved ultrasound techniques,
higher availability of examinations, and higher awareness of
patients today allow for early institution of appropriate treat-
ment. The above-described observations of the present authors,
as well as data from world literature, indicate a need for further
immunological and genetic investigations aiming at under-
standing the nature of a protective role of coexistence of an
autoimmune disease and thyroid cancer. It should be remem-
bered, however, that the continuously low number of patients,
high costs of genetic probes, and ambiguous diagnostic proto-
col limit the use of such observations in clinical practice.
Hence, in view of the high percentage of PTC in HT and
incidence of complications following total thyroidectomies that
is comparable to that observed in operations performed in
patients with nonneoplastic goiter [39–41], the optimum strat-
egy of surgical treatment of Hashimoto thyroiditis in such
patients should include total thyroidectomy and preventive
central compartment lymphadenectomy, which is of impor-
tance in assessing tumor stage and determining recommenda-
tions for further adjuvant therapy. Total thyroidectomy along
with excision of central compartment lymph nodes may result
in damaging recurrent laryngeal nerves and accidental excision
of inferior parathyroids glands. Nevertheless, the incidence of
such complications in referral centers is low.
The literature on the subject increasingly more often
presents reports stating that primary total thyroidectomy allows
not only for treating the neoplastic disease already diagnosed
based on the FNAB result but also contributes to a decrease in
reoperation rate due to postoperative diagnosis of thyroid can-
cer. Analyzing this aspect, we may say that primary total
thyroidectomy also limits the number of permanent complica-
tions, which in a significant percentage of cases pose a consid-
erable threat in the course of reoperation. In our opinion, the
above-described rationale provides a foundation for consider-
ing radical surgical treatment in cases of nodular lesions being
present in immunologically altered thyroid gland.
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